The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
A large batch of ultrasound transmission gel from Pharmaceutical Innovations Inc. in Newark, NJ has been seized in response to an FDA warning that the gel contained dangerous bacteria.
